http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
만성 신부전 환자에서 빈혈 개선에 따른 혈장 수용성 interleukin-2 수용체 농도의 변화
조영일,긴경수,최영숙 건국대학교 1996 學術誌 Vol.40 No.2
To evaluate the effect of anemia on the immune system in chronic renal failure (CRF) patients on hemodialysis (HD), we measured plasma sIL-2R levels in 10 CRF patients with anemia and 10 CRF patients without anemia on HD. In 10 CRF patients with anemia, plasma sIL-2R levels were measured also after correction by transfusion of packed RBCs or subcutaneous injection of rH-EPO. Plasma sIL-2R level was measured using h-IL-2R ELISA kit (Boehringer Manheim Biochemical, Germany) before and after correction of anemia. The results were as follows : Plasma sIL-2R level was 287.36±70.18 pmol/L in uremic patients with anemia and 211.35±49.85 pmol/L in uremic patients without anemia (p<0.05). After correction of anemia, plasma sIL-2R level was 299.55±98.85 pmol/L in "Low-Hct" group (Hct<26%) and 222.61 ±60.05 pmol/L in "High-Hct" group (Hct≥26%) (p<0.05). In anemic patients, plasma sIL-2R level before correction of anemia was 290.50±80.25 pmol/L and after correction of anemia was 243.74± 64.89 pmol/L (p<0.05). On conclusion, plasma sIL-2R level was higher in CRF patients with anemia than CRF patients without anemia. Plasma sIL-2R level in CRF patients with anemia became lowerd after correction of anemia. Key Word : Chronic renal failure, Plasma soluble IL-2 receptor, Anemia, Immune system.
李承務,趙英一,任侑鎭 연세대학교 대학원 1977 延世論叢 Vol.14 No.2
This investigation was carried out in order to remove the hazardous inorganic metallic ion such as Cu (II) in waste Irater by the technique of ionic flotation with a surfactant, DBS. Cu (II) was removed at top of the column, in which Cu (II) being attached on the surfaces of buffles rising from the air distributor at the bottom of a vertical column. In this experiment, when feed position leas positioned at the midpoint of foam height, the formate and the DBS concentration in the drain were reduced with increasing foam height. The Cu (II) concentration in the drain was also reduced in proportion to the logarithm of air flow rate. From the experimental result, the removal ratio, Cu (II) in the formate to that in the feed, E, was related to the DBS concentration in the feed, Cfd, Cu (II) concentration in the feed, Cfc, andair flow rate, G, as the following empirical equation: E= 0.123 (Cfd/Cfc) +0.148 ln (G/100)
Inhibition of Human Malignant Glioma Growth in Vivo by Human Recombinant Plasminogen Kringles 1-3
Joe, Young-Ae,Hong, Yong-Kil,Chung, Dong-Sup,Yang, Youn-Joo,Kang, Joon-Ki,Lee, Youn-Soo,Chang, Soo-Ik,You, Weon-Kyoo,Lee, Hyo-sil,Chung, Soo-Il 가톨릭대학교 2000 Bulletin of The Catholic Research Institutes of Me Vol.28 No.-
Human malignant gliomas are highly vascularized and aggressive tumors. Aniogenesis inhibitors have been shown to induce regression of a variety of primary and metastatic-tumors in vivo. However, their usefulness in treating brain tumors is not well understood. Aniostatin, a multiple krinlge (1-4 of 5)-containing fragment of plasminogen, is one of the highly effective natural cryptic angiogenesis inhibitors. In our study, the therapeutic efficacy of non-glycosylated and small molecular size recombinant kringles 1-3 (rPK1-3) was examined in the treatment of brain tumors generated by stereotactic intracerebral implantation of U-87 human glioma cells in nude mice. Mice bearing tumors 7 days post-implant were treated daily with rPK1-3 (100 mg/kg) s.c. for 21 days. Treated animals showed suppressed brain tumor growth by greater that 71.2% along with a 3-fold increase of apoptotic index and suppressed vascularization by 78.9%, without any observable signs of toxicity. Analysis of bFGF and VEGF expression in the tumors of treated animals using immunohistochemical methods showed near complete absence of growth factors. Our results indicate that the non-glycosylated, small molecular size rPK1-3 is an efficient tumoristatic agent for the treatment of intracranial human glioma xenografts in mice and might provide new strategies for the treatment of brain tumors. (International Journal of Cancer 82:694-699, 1999)